Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.730
0.00 (0.00%)
Oct 14, 2026, 10:45 AM EDT - Market open
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
3.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
APVO News
- 2 hours ago - Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting - Accesswire
- 20 days ago - Aptevo Therapeutics advances trispecific candidate toward clinical development - TheFly
- 20 days ago - Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development - Accesswire
- 5 weeks ago - Aptevo AML data ‘highly encouraging,’ says Roth Capital - TheFly
- 5 weeks ago - Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia - TheFly
- 5 weeks ago - Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - Accesswire
- 7 weeks ago - Aptevo Therapeutics files to sell 6.44M shares of common stock for holders - TheFly
- 1 month ago - Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds - TheFly